News About: Pharm. Industry
Foreign investors target Chong Kun Dang Pharmaceutical
Foreign investors have been aggressively buying shares of Chong Kun Dang Pharmaceutical and Hanmi Pharm, according to the recent survey of Yakup Shinmoon.
Stock price of Chong Kun Dang is hovering around 32,000 won...
ReNu MultiPlus is safe, Bausch & Lomb Korea says
After Bausch & Lomb Inc. decided to recall its ReNu with MoistureLoc contact lens solution in the U.S. market, which has been linked to dozens of cases of a serious eye infection, ReNu MultiPlus is gradually restoring...
Novartis and Seoul Asan hospital to agree clinical R&D.Novartis Korea and Seoul Asan hospital have singed an agreement for the clinical R&D cooperation covering that Seoul Asan hospital establishes "Novartis Clinical Research Office...
|
Korea needs to learn from Novartis's 60-year natural products research
Korea aims to become one of the world's top seven countries in natural substance research and development by developing at least six new medicines by 2010.
Under the projects, the Korean government plans to develop...
Stocks of pharmaceutical industry skid
The recent bioequivalence testing scandal and the U.S.'s pressure on Korea's drug pricing in the health insurance system through free trade agreement have dealt a severe blow to share prices of major pharmaceutical co...
Pharmaceutical patent issue emerged as a key KORUS FTA agenda.
The pharmaceutical patent issues have been surfaced to the Korea and U. S. free trade agreement (FTA) as a key agenda.
In a few round of the KORUS FTA talks in Washington DC, the U. S. side called for the patent to...
Choongwae borrows 34.8 billion won from local banks
Choongwae Pharm said on June 7 that it succeeded in bring in a total of 34.8 billion won from the Korea Development Bank's private equity fund (PEF) and Uri Bank in the form of capital investment.
Choongwae Pharm e...
Kim Sang-jin named Johnson&Johnson Hong Kong Ltd.
Kim Sang-jin, managing director of Johnson&Johnson Korea, has been named to head Johnson&Johnson Hong Kong Ltd. from June 8.
A graduate of Seoul National University in 1989, Kim, 41, joined Johnson&Johnson Korea in...
Local phase III study of Xeloda confirmed stomach cancer therapy.
A multinational clinical study was completed by a Korean researcher for the first time in Korea and presented at an international conference.
Roche Korea announced on June 7 that Prof. Kang Yun-goo of the oncology ...
Local drug industry credibility and product quality far improved.
It was reported that the local pharmaceutical industries had made a remarkable investment for their operational and product qualities through an adoption of cGMP. EUGMP standards in their plants not only for their fin...
